Clinical Trial Update: Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluate erlotinib as neoadjuvant therapy in patients with stage IIIA, N2-positive non-small cell lung cancer, reporting on its efficacy i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Lung Neoplasms, Erlotinib | Phase 2 | Status: COMPLETED